Signal12 is a Phase 3-ready ophthalmic drug company. Our proprietary topical drug, Pro-ocular™, has proven safe and effective in multiple Phase 2 clinical studies, demonstrating significant reductions in the signs and symptoms of ocular Graft-versus-Host Disease (oGvHD)—a chronic, debilitating condition following an allogeneic stem cell transplant. Pro-ocular™ is the only effective treatment for oGvHD, employing transappendageal delivery to precisely target the ophthalmic branch of the trigeminal nerve
Contact Neil Edwards, CFO, for more information at nedwards@signal12inc.com.
Company Details
- Employees
- 1
- Address
- Greenwich, Ct, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.signal12inc.com
- HQ
- Greenwich, CT
Signal12 Questions
Signal12's website is https://www.signal12inc.com
Signal12's LinkedIn profile is https://www.linkedin.com/company/signal-12
Signal12 has
1 employees.
View email and phone details for 1
employees at Signal12.
Signal12's industry is
Pharmaceutical Manufacturing
Signal12's top competitors are
Spencer Trask & Co.,
Orasis Pharmaceuticals,
Sydnexis,
Ophthalmology 360®,
Lenz Therapeutics,
Trialclarity,
Deeper Than Dough,
Vesselon,
Oculis,
Bausch + Lomb.
Signal12's categories are Pharmaceutical Manufacturing
